摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-cyclohexylpiperazin-1-yl)ethanamine | 937650-04-9

中文名称
——
中文别名
——
英文名称
2-(4-cyclohexylpiperazin-1-yl)ethanamine
英文别名
2-(4-cyclohexylpiperazin-1-yl)ethylamine
2-(4-cyclohexylpiperazin-1-yl)ethanamine化学式
CAS
937650-04-9
化学式
C12H25N3
mdl
——
分子量
211.351
InChiKey
CDCBWZFCCPFAPS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    32.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(4-cyclohexylpiperazin-1-yl)ethanamine吡啶三氟乙酸 作用下, 以 N,N-二甲基甲酰胺甲苯 为溶剂, 反应 4.0h, 生成
    参考文献:
    名称:
    Analogues of σ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Added Polar Functionality and Reduced Lipophilicity for Potential Use as Positron Emission Tomography Radiotracers
    摘要:
    1-Cyclohexyl-4[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high degree of lipophilicity, novel analogues of 1 with reduced lipophilic character were designed by substituting methylene groups with more polar functional groups in the propylene linker and at the tetralin C4 position. For the chiral analogues, separate enantiomers exhibited substantial and roughly equal affinities within a given receptor subtype, with the greatest difference observed for compound 9 at sigma(1) (7.5-fold; (-)-(S)-9 K(i) = 94.6 nM, (+)-(R)-9 K(i) = 12.6 nM). Compound (-)-(S)-9 was also found to be the most sigma(2)-selective agent (sigma(2) K(i) = 5.92 nM), to possess a lipophilicity consistent with entry into tumor cells (log D(7.4) = 2.38), and to show minimal antiproliferative activity. However, (-)-(S)-9 exhibited moderate activity (EC(50) = 8.1 mu M) at the P-gp efflux pump.
    DOI:
    10.1021/jm1013133
  • 作为产物:
    描述:
    1-环己基哌嗪 在 borane dimethyl sulfide complex 、 三乙胺 作用下, 以 四氢呋喃 为溶剂, 生成 2-(4-cyclohexylpiperazin-1-yl)ethanamine
    参考文献:
    名称:
    Analogues of σ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Added Polar Functionality and Reduced Lipophilicity for Potential Use as Positron Emission Tomography Radiotracers
    摘要:
    1-Cyclohexyl-4[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high degree of lipophilicity, novel analogues of 1 with reduced lipophilic character were designed by substituting methylene groups with more polar functional groups in the propylene linker and at the tetralin C4 position. For the chiral analogues, separate enantiomers exhibited substantial and roughly equal affinities within a given receptor subtype, with the greatest difference observed for compound 9 at sigma(1) (7.5-fold; (-)-(S)-9 K(i) = 94.6 nM, (+)-(R)-9 K(i) = 12.6 nM). Compound (-)-(S)-9 was also found to be the most sigma(2)-selective agent (sigma(2) K(i) = 5.92 nM), to possess a lipophilicity consistent with entry into tumor cells (log D(7.4) = 2.38), and to show minimal antiproliferative activity. However, (-)-(S)-9 exhibited moderate activity (EC(50) = 8.1 mu M) at the P-gp efflux pump.
    DOI:
    10.1021/jm1013133
点击查看最新优质反应信息

文献信息

  • Small-Molecule Inhibition of the UNC119-Cargo Interaction
    作者:Tom Mejuch、Guillaume Garivet、Walter Hofer、Nadine Kaiser、Eyad K. Fansa、Christiane Ehrt、Oliver Koch、Matthias Baumann、Slava Ziegler、Alfred Wittinghofer、Herbert Waldmann
    DOI:10.1002/anie.201701905
    日期:2017.5.22
    chaperones UNC119A/B regulate the cellular distribution and signaling of N-myristoylated proteins. Selective small-molecule modulators of the UNC119-cargo interaction would be invaluable tools, but have not been reported yet. We herein report the development of the first UNC119-cargo interaction inhibitor, squarunkin A. Squarunkin A selectively inhibits the binding of a myristoylated peptide representing
    N-末端肉豆蔻酰化促进膜的结合和蛋白质(特别是Src家族激酶)的活性,但是其潜在机制才刚刚被人们理解。伴侣UNC119A / B调节N-肉豆蔻酰化蛋白的细胞分布和信号传导。UNC119-货物相互作用的选择性小分子调节剂将是无价的工具,但尚未有报道。我们在此报告了第一个UNC119-货物相互作用抑制剂squarunkin A的开发。SquarunkinA用IC 50选择性抑制代表Src激酶N端的肉豆蔻酰化肽与UNC119A的结合值为10 nm。它与细胞裂解物中的UNC119蛋白结合,并干扰Src激酶的激活。我们的研究结果表明,对UNC119-货物相互作用的小分子抑制可能为调节Src激酶的活性提供新的机会,而Src激酶的活性与直接抑制酶激酶的活性无关。
  • Cinnamic Acid Amide Derivative
    申请人:NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    公开号:US20150322024A1
    公开(公告)日:2015-11-12
    The present invention provides a cinnamic acid amide derivative having an excellent analgesic action. The cinnamic acid amide derivative of the present invention is a compound showing excellent analgesic actions to not only a nociceptive pain model animal but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains.
    本发明提供一种具有出色镇痛作用的肉桂酸酰胺衍生物。本发明的肉桂酸酰胺衍生物是一种化合物,不仅对伤害性疼痛模型动物,而且对神经病理性疼痛模型动物显示出出色的镇痛作用,非常适用于治疗各种急性或慢性疼痛或神经病理性疼痛的药剂。
  • CINNAMIC ACID AMIDE DERIVATIVE
    申请人:Nippon Zoki Pharmaceutical Co., Ltd.
    公开号:EP2940003A1
    公开(公告)日:2015-11-04
    The present invention provides a cinnamic acid amide derivative having an excellent analgesic action. The cinnamic acid amide derivative of the present invention is a compound showing excellent analgesic actions to not only a nociceptive pain model animal but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains.
    本发明提供了一种具有优异镇痛作用的肉桂酸酰胺衍生物。本发明的肉桂酸酰胺衍生物是一种化合物,不仅对痛觉痛模型动物,而且对神经病理性痛模型动物都有很好的镇痛作用,作为治疗各种表现为急性或慢性疼痛或神经病理性疼痛的疼痛疾病的药物非常有用。
  • EP2940003
    申请人:——
    公开号:——
    公开(公告)日:——
  • US9540338B2
    申请人:——
    公开号:US9540338B2
    公开(公告)日:2017-01-10
查看更多